ArticleBone2010
Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.
Article in Bone, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Pooled it
- Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.The Journal of bone and joint surgery. American volume · 2013Pooled it
- Examining the Relationships Between Bone Tissue Composition, Compositional Heterogeneity, and Fragility Fracture: A Matched Case-Controlled FTIRI Study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Trial
- Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Trial
- Mechanism-Oriented Biomaterial Strategies for Bone Regeneration in BRONJ: From Pathological Barriers to Evidence-Matched Repair.Biomolecules · 2026Review
- Article
- Bone hydration: How we can evaluate it, what can it tell us, and is it an effective therapeutic target?Bone reports · 2022Article
- Poor bone matrix quality: What can be done about it?Current osteoporosis reports · 2021Review
- Alendronate enhances osseointegration in a murine implant model.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2021Article
- Treatments of osteoporosis increase bone material strength index in patients with low bone mass.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Article
- 6'-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding.Bone reports · 2020Article
- Article
- The Role of Lower-Limb Geometry in the Pathophysiology of Atypical Femoral Fracture.Current osteoporosis reports · 2019Review
- Young's modulus and hardness of human trabecular bone with bisphosphonate treatment durations up to 20 years.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Article
- Cathepsin K inhibition preserves compressive load in lumbar vertebrae of osteoporotic monkeys.Bone reports · 2018Article
- Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate.Calcified tissue international · 2017Article
- High-scale yield of nano hydroxyapatite through combination of mechanical activation and chemical dispersion.Journal of materials science. Materials in medicine · 2017Article
- Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties.Scientific reports · 2017Article
- Compressive loading of the murine tibia reveals site-specific micro-scale differences in adaptation and maturation rates of bone.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Article
- Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.BioMed research international · 2017Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Bone loss and alterations in bone quality are major causes leading to bone fragility in postmenopausal women. Although bisphosphonates are well known to reduce bone turnover and prevent bone loss in postmenopausal osteoporosis, their effects on other bone properties are not fully characterized. Changes in bone mineral and matrix properties may contribute to the anti-fracture efficacy observed with bisphosphonate treatments. The aim of this work was to analyze the effect of a 1-year treatment with either alendronate or risedronate, at low and high doses, on spatially resolved bone material and compositional properties that could contribute to the fracture efficacy of these agents. Distal tibias from 30 normal beagles that had been treated daily for 1 year with oral doses of vehicle (Veh), alendronate (Aln) at 0.2 or 1 mg/kg, and risedronate (Ris) at 0.1 or 0.5 mg/kg were analyzed by Fourier Transform Infrared imaging (FTIRI) to assess the changes in both mineral and matrix properties in discrete bone areas. The widths at half maximum of the pixel histograms for each FTIRI parameter were used to assess the heterogeneity of the bone tissue. Aln and Ris increased the mineral content and the collagen maturity mainly in cancellous bone and at the endocortical surface. Significant differences were observed in the mineral content and in the hydroxyapatite crystallinity distribution in bone tissue, which can contribute to reduced ductility and micro-crack accumulation. No significant differences were observed between low and high dose nor between Aln and Ris treatments. These results show that pharmacologic suppression of bone turnover increases the mineral and matrix bone tissue maturity in normal cancellous and endocortical bone areas where bone turnover is higher. These positive effects for decreased fracture risk are also associated with a loss of bone heterogeneity that could be one factor contributing to increased bone tissue brittleness and micro-crack accumulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.